Targets › TTK
2 programs from 2 companies in 4 trials: 3 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.
Involved in mitotic spindle assembly checkpoint signaling, a process that delays anaphase until chromosomes are bioriented on the spindle, and in the repair of incorrect mitotic kinetochore-spindle microtubule attachments. Phosphorylates MAD1L1 to promote the mitotic spindle assembly checkpoint. (UniProt, P33981)
Open in Phaseline: the race on TTK, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| SillaJen | BAL0891 Dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1) | TTK, PLK1 | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| Treadwell Therapeutics | CFI-402257 TTK inhibitor | TTK | Phase 1 | Advanced Solid Tumor; Breast Cancer | – |
Advanced Solid Tumor (2) Breast Cancer (2)
mixed (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.